Emergent BioSolutions (EBS) Tops Q3 EPS by 101c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.46 -0.82%
Revenue Growth %: +32.0%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Revenue Growth %: +32.0%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $1.06, $1.01 better than the analyst estimate of $0.05. Revenue for the quarter came in at $231.1 million versus the consensus estimate of $203.67 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- FTI Consulting names Dean Felton as Senior Managing Director in Australia
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
